Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

How low is safe? The frontier of very low (<30 mg/dL) LDL cholesterol
Angelos Karagiannis, Anurag Mehta, Devinder S. Dhindsa, et al.
European Heart Journal (2020) Vol. 42, Iss. 22, pp. 2154-2169
Open Access | Times Cited: 39

Showing 1-25 of 39 citing articles:

Side effects of statins: from pathophysiology and epidemiology to diagnostic and therapeutic implications
Massimiliano Ruscica, Nicola Ferri, Maciej Banach, et al.
Cardiovascular Research (2022) Vol. 118, Iss. 17, pp. 3288-3304
Open Access | Times Cited: 102
There is urgent need to treat atherosclerotic cardiovascular disease risk earlier, more intensively, and with greater precision: A review of current practice and recommendations for improved effectiveness
Michael E. Makover, Michael D. Shapiro, Peter P. Tóth
American Journal of Preventive Cardiology (2022) Vol. 12, pp. 100371-100371
Open Access | Times Cited: 59
Inclisiran: A New Strategy for LDL-C Lowering and Prevention of Atherosclerotic Cardiovascular Disease
Michael Albosta, Jelani Grant, Pam R. Taub, et al.
Vascular Health and Risk Management (2023) Vol. Volume 19, pp. 421-431
Open Access | Times Cited: 22
Left Main Coronary Artery Calcium and Diabetes Confer Very-High-Risk Equivalence in Coronary Artery Calcium >1,000
Alexander C. Razavi, Leslee J. Shaw, Daniel S. Berman, et al.
JACC. Cardiovascular imaging (2024) Vol. 17, Iss. 7, pp. 766-776
Closed Access | Times Cited: 9
PCSK9 Inhibition and Risk of Diabetes: Should We Worry?
Stefano Carugo, Cesare R. Sirtori, Alberto Corsini, et al.
Current Atherosclerosis Reports (2022) Vol. 24, Iss. 12, pp. 995-1004
Open Access | Times Cited: 30
Efficacy and safety of low levels of low-density lipoprotein cholesterol: trans-ancestry linear and non-linear Mendelian randomization analyses
Hongwei Liu, Jianxin Li, Fangchao Liu, et al.
European Journal of Preventive Cardiology (2023) Vol. 30, Iss. 12, pp. 1207-1215
Closed Access | Times Cited: 18
Efficacy and safety of inclisiran in stroke or cerebrovascular disease prevention: a systematic review and meta-analysis of randomized controlled trials
Min Luo, Yihan Liu, Xinyi Xu, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 17
High-density lipoproteins, lipoprotein(a), and remnant cholesterol: new opportunities for reducing residual cardiovascular risk
Filippo Crea
European Heart Journal (2023) Vol. 44, Iss. 16, pp. 1379-1382
Open Access | Times Cited: 15
Whether and Why Do We Need a Vaccine Against Atherosclerosis? Can We Expect It Anytime Soon?
Stanisław Surma, Amirhossein Sahebkar, Maciej Banach
Current Atherosclerosis Reports (2024)
Open Access | Times Cited: 5
Reducing LDL-Cholesterol to Very Low Levels: Sailing Between Established Benefits and Potential Risks
Stefania Angela Di Fusco, Massimo Volpe, Federico Nardi, et al.
High Blood Pressure & Cardiovascular Prevention (2025)
Closed Access
Inclisiran: How Widely and When Should We Use It?
Angela Pirillo, Alberico L. Catapano
Current Atherosclerosis Reports (2022) Vol. 24, Iss. 10, pp. 803-811
Open Access | Times Cited: 21
Low-density lipoprotein cholesterol levels and risk of incident dementia: a distributed network analysis using common data models
Minwoo Lee, Kyung Joo Lee, Jinseob Kim, et al.
Journal of Neurology Neurosurgery & Psychiatry (2025), pp. jnnp-334708
Closed Access
Residual Atherosclerotic Cardiovascular Disease Risk: Focus on Non-High-Density Lipoprotein Cholesterol
Yonghong Luo, Daoquan Peng
Journal of Cardiovascular Pharmacology and Therapeutics (2023) Vol. 28
Open Access | Times Cited: 8
Prevention of Coronary Heart Disease: A Translational Clinical Challenge
Julie Giannini, Janae Padilla, R. Philip Eaton, et al.
World Journal of Cardiovascular Diseases (2022) Vol. 12, Iss. 01, pp. 11-23
Open Access | Times Cited: 11
Comparison of low-density lipoprotein cholesterol equations in patients with dyslipidaemia receiving cholesterol ester transfer protein inhibition
Seth S. Martin, Marc Ditmarsch, Mark Simmons, et al.
European Heart Journal - Cardiovascular Pharmacotherapy (2022) Vol. 9, Iss. 2, pp. 148-155
Open Access | Times Cited: 11
2022 Saudi Guidelines for the Management of Dyslipidemia
Jamilah AlRahimi, Shukri AlSaif, Mirvat Alasnag, et al.
Heart Views (2023) Vol. 24, Iss. 2, pp. 67-92
Open Access | Times Cited: 6
Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition: The Big Step Forward in Lipid Control
Rishi Rikhi, Michael D. Shapiro
European Cardiology Review (2023) Vol. 18
Open Access | Times Cited: 6
Current Insights on Dyslipidaemia Management for Prevention of Atherosclerotic Cardiovascular Disease: A Malaysian Perspective
Wan Azman Wan Ahmad, Azhari Rosman, Sunita Bavanandan, et al.
Malaysian Journal of Medical Sciences (2023) Vol. 30, Iss. 1, pp. 67-81
Open Access | Times Cited: 4
Effect of alirocumab on cataracts in patients with acute coronary syndromes
Gaspard Suc, Gregory G. Schwartz, Shaun G. Goodman, et al.
BMC Ophthalmology (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 4
Review of Recent Literature and Updates in Nonstatin Cholesterol Management
Elisabeth M Wang, Bernadette Asias-Dinh, Natalie Rosario
Mayo Clinic Proceedings (2024) Vol. 99, Iss. 9, pp. 1449-1468
Closed Access | Times Cited: 1
Effect of rosuvastatin versus atorvastatin on new-onset diabetes mellitus in patients treated with high-intensity statin therapy for coronary artery disease: a post-hoc analysis from the LODESTAR randomized clinical trial
Sung‐Jin Hong, Yong‐Joon Lee, Woong Chol Kang, et al.
Cardiovascular Diabetology (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 1
Lipoprotein(a) in interventional cardiology: identifying patients at highest risk of recurrent cardiovascular events through early recognition – a case based review
Mick Renkens, Casper F. Coerkamp, Lars S. Witte, et al.
Expert Review of Cardiovascular Therapy (2024) Vol. 22, Iss. 8, pp. 353-366
Open Access | Times Cited: 1
Cholesterol: the race to the bottom
Eugene Braunwald
European Heart Journal (2021) Vol. 42, Iss. 45, pp. 4612-4613
Closed Access | Times Cited: 10
Targeting PCSK9 With Antibodies and Gene Silencing to Reduce LDL Cholesterol
Connie B. Newman, Jonathan A. Tobert
The Journal of Clinical Endocrinology & Metabolism (2022) Vol. 108, Iss. 4, pp. 784-790
Closed Access | Times Cited: 7
Dyslipidaemias in stroke, chronic kidney disease, and aortic stenosis: the new frontiers for cholesterol lowering
Filippo Crea
European Heart Journal (2021) Vol. 42, Iss. 22, pp. 2137-2140
Open Access | Times Cited: 9
Page 1 - Next Page

Scroll to top